22 August 2018

In World Journal of Urology Jurgen Fütterer and colleagues described that functional imaging is of added value in patients with oligometastatic prostate cancer.

Abstract

Purpose
Along with a number of other malignancies, the term "oligometastatic" prostate cancer has recently emerged. It represents an attempt to define a subtype of cancer with a limited metastatic load that might perform more favorably than a distinctly disseminated disease, or even one that may be managed in a potentially curative way. Since there is currently a knowledge gap of what imaging modalities should be utilized to classify patients as having this type of tumor, we aimed to shed light on the role of conventional and marker-based imaging in the setting of synchronous oligometastatic prostate cancer as well as summarize the available evidence for its clinical application.
Methods
A literature search on December 15th 2017 was conducted using the Pubmed database.
Results
Functional imaging techniques like 68Ga PSMA has currently been shown the best detection rates for the assessment of nodal, bone and visceral metastases, especially for smaller lesions at low PSA levels.
Conclusions
Functional imaging helps detect low-burden disease metastatic patients. However, these imaging modalities are not available in every center and thus clinicians may be prone to prescribe systemic treatment rather than referring patients for cytoreductive treatments. We hope that the ongoing prospective trials will help guide clinicians in making a more personalized management of synchronous metastatic patients.

Publication
Imaging modalities in synchronous oligometastatic prostate cancer.
Futterer JJ, Surcel C, van den Bergh R, Borgmann H, Briganti A, Gandaglia G, Kretschmer AOst P, Sooriakumaran P, Tilki D, Valerio M, Ploussard G, De Visschere PJL, Tsaur IEAU-YAU Prostate Cancer Working Party.
 
This research was conducted within the theme Urological cancers.

Related news items


Millions of euros for study of laser treatment for glioblastoma

2 April 2021 A research group from Radboudumc and UMC Utrecht is to investigate laser treatment of a rare brain tumor, glioblastoma. 3.9 million euros has been made available for the research by Zorginstituut Nederland and ZonMw, under the auspices of the Subsidy Scheme for Promising Care. read more

Jurgen Fütterer appointed Professor of Image-Guided Oncological Interventions

26 February 2020 RIHS researcher Fütterer is an interventional radiologist and an expert in the field of cancer imaging techniques, image-guided interventions and robotics. He is also Professor at the Robotics and Mechatronics Group at the University of Twente. read more

SPL Medical starts clinical trial with contrast agent ferrotran

11 February 2020 SPL Medical is starting an international registration study for its contrast agent Ferrotran. The study is being conducted in ten hospitals in Germany, Switzerland and the Netherlands. RIHS researcher Jelle Barentsz discovered the value of this drug in patients with lymph node metastases. read more

New Guidelines for the detection of prostate cancer MRI instead of tissue samples

3 February 2020 The module on diagnostic prostate MRI for the NVU guidelines for prostate carcinoma took effect on 29 January 2020. The development of these guidelines is due in part to the efforts of RIHS researcher Jelle Barentsz and Ivo Schoots (Erasmus MC). read more

Jelle Barentsz's trilogy of educational papers in European Urology

12 December 2019 Recently, a trilogy of educational papers by our full professor Jelle Barentsz has been published in European Urology. The publications address what urologists need to know about prostate-MRI. read more

Algorithm calculates the presence and aggressiveness of prostate tumors

14 May 2019 A computer program that analyzes MRI images can reliably map the presence and even the aggressiveness of a prostate tumor. This is what Radboudumc researchers and international colleagues have published in the scientific journal Investigative Radiology. read more